AC
TEVA icon

Avestar Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Avestar Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-132
Closed -$1.59K – 968
2019
Q1 		$1K Buy
132
+49
+59% +$864 ﹤0.01% 789
2018
Q4 		$1K Sell
83
-34
-29% -$697 ﹤0.01% 774
2018
Q3 		$1K Buy
117
+11
+10% +$255 ﹤0.01% 769
2018
Q2 		$1K Buy
+106
New +$2.16K ﹤0.01% 819
2018
Q1 		– Hold
0
– – – 776

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Avestar Capital's TEVA Position: Q2 2019 in Review

Avestar Capital sold out of Teva Pharmaceuticals (TEVA) in Q2 2019, closing a stake of 132 shares — an estimated $1.59K sold.

Avestar Capital first reported a position in TEVA in Q2 2018 and held it in 4 quarters. The position peaked at $1K in Q1 2019. 452 funds tracked by Wall St. Rank hold TEVA as of Q2 2019.

  • Avestar Capital reported no remaining Teva Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Avestar Capital sold 132 Teva Pharmaceuticals shares in Q2 2019, an estimated $1.59K.
  • Avestar Capital first reported a position in Teva Pharmaceuticals in Q2 2018 and held it in 4 quarters.
  • Avestar Capital's Teva Pharmaceuticals position peaked at $1K in Q1 2019.
  • 452 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2019.

Based on Avestar Capital's 13F filing for Q2 2019, filed 6 Aug 2019.